Neurobiological Predictors of Huntington's Disease (PREDICT-HD)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

1700 participants

Study Classification

OBSERVATIONAL

Study Start Date

2002-08-31

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this trial is to study early brain and behavioral changes in people who have the gene expansion for Huntington's disease, but are currently healthy and have no symptoms.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Family Health After Predictive Huntington Disease (HD) Testing

NCT00075140

Huntington Disease

COMPLETED

A Pre-Cellular Therapy Observational Study in Early Huntington's Disease

NCT01937923

Huntington Disease

COMPLETED

Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People With Premanifest and Early Stage HD

NCT03306888

Huntington's Disease

COMPLETED PHASE1/PHASE2

Preparing for Prevention of Huntington's Disease (PREVENT-HD)

NCT04818060

Huntington Disease

COMPLETED

Study of Biomarkers That Predict the Evolution of Huntington's Disease

NCT01412125

Huntington Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Huntington's Disease (HD) is an inherited disease that causes changes in a person's ability to control movements, thinking, and feelings. The intent of this study is to learn more about the beginning changes in thinking skills, emotional regulation, and brain structure and function as a person begins the transition from health to HD.

Preliminary studies indicate that people with HD may have marked decline before an actual diagnosis. This study will help reveal the earliest indicators of the disease and what factors influence the age at which a person carrying the gene develops the disease. It is necessary to get information on the early stages of HD in order to develop drugs that can slow or postpone the onset of HD. The investigators hope this study will provide essential information for future trials of experimental drugs for HD.

During this study, participants will undergo several detailed tests, including MRI scans of the brain, cognitive assessments, physical exams, bio specimen (blood, urine, cerebral spinal fluid) collection and neurological and psychiatric testing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Huntington Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* men and women at risk for HD, who have been tested for the HD gene mutation, and who have not been diagnosed with symptoms of HD (CAG ≥36 for CAG-expanded group or CAG \<36 for CAG-norm group).

Exclusion Criteria

* diagnosis of manifest HD (at least 50% confidence by neurologist that symptoms are present);
* clinical evidence of unstable medical or psychiatric illness (including substance abuse);
* history of sever learning disability or mental retardation;
* history of other CNS disease or event (e.g., seizures or head trauma);
* current treatment with antipsychotic medications, including the traditional neuroleptics such as haloperidol as well as the atypical antipsychotics risperidone, clozapine, quetiapine, and olanzapine;
* treatment with phenothiazine-derivative antiemetic medications such as prochlorperazine, metoclopramide, promethazine, and Inapsine on a regular basis (greater than 3 times per month);

* Current use of anti-coagulants
* Current use of anti-platelets
* Unable to provide consent for him/herself

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No